title: Cardiotoxicity of molecular-targeted drug therapy.
abstract: Cardiotoxicity is a well-known side-effect described in patients receiving various antineoplastic agents. With the abundance of clinical research and a heavy focus on drug development over the past decade, there has been a major shift in the use of non-specific cytotoxic drugs to molecular-targeted drug therapy. However, as a result, it has become clear that these drugs have numerous adverse effects, both on-target and off-target. Small-molecule tyrosine kinase inhibitors and other molecular-targeted agents, including monoclonal antibodies, have been the primary agents associated with cardiotoxicity. As more molecular-targeted therapies are developed, early recognition and management of drug-related cardiotoxicity will be extremely important in order to reduce morbidity and mortality. Pre-treatment evaluation with a surface electrocardiogram, echocardiography, cardiac history, and comprehensive review of concomitant medications are the current mainstay of treatment. However, much is still unknown about the potential cardiotoxic side-effects of these drug and optimal management. In the present article, we aim to review the cardiovascular implications and related cardiotoxicities associated with molecular target-based chemotherapeutic agents, with special emphasis on hypertension, cardiac dysfunction, and QT prolongation. Their implication, mechanism, and management are discussed where possible.
authors: St. Mary's Medical Center, San Francisco, CA, U.S.A.
authors: Duong L
authors: DL
authors: Le
authors: St. Mary's Medical Center, San Francisco, CA, U.S.A.
authors: Huynh
authors: H
authors: Cao
authors: St. Mary's Medical Center, San Francisco, CA, U.S.A Radiobiology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, U.S.A. yangl@cpmcri.org.
authors: Li-Xi
authors: LX
authors: Yang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects / Q000379:methods
chemical_list: D000970:Antineoplastic Agents
keywords: Cardiotoxicity; VEGF; cardiac dysfuntion; hypertension; molecular-targeted therapy; review